期刊
EBIOMEDICINE
卷 11, 期 -, 页码 302-306出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2016.08.024
关键词
Abatacept; Rheumatoid arthritis; Disease activity; DAS28; Longitudinal data; Drug retention; Response rate
Background: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. Weaimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD). Methods: Pooled analysis of nine national registries of patients with diagnosis of RA, who initiated Abatacept and had at least two measures of disease activity (DAS28). We used growth mixture models to identify groups of patients with similar courses of treatment response, and examined these patients' characteristics and effectiveness outcomes. Findings: We identified three types of treatment response trajectories: 'gradual responders' (GR; 3576 patients, 91.7%) had a baseline mean DAS28 of 4.1 and progressive improvement over time; 'rapid responders' (RR; 219 patients, 5.6%) had higher baseline DAS28 and rapid improvement in disease activity; 'inadequate responders' (IR; 103 patients, 2.6%) had high DAS28 at baseline (5.1) and progressive worsening in disease activity. They were similar in baseline characteristics. Drug discontinuation for ineffectiveness was shorter among inadequate responders (p = 0.03), and EULAR good or moderate responses at 1 year was much higher among 'rapid responders' (p < 0.001). Interpretation: Clinical information and baseline clinical characteristics do not allow a reliable prediction of which trajectory the patients will follow after bDMARD initiation. (C) 2016 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据